Sun Pharmaceutical Industries Ltd
Ticker: SUNPHARMA
Decent
68/100
☆ Add to Watchlist
Investing Reference
Price
1655.10
Market Cap
397113.93
Debt/Equity
0.0326
ROE %
15.656
PB
5.4785
Promoter %
54.479
Pledge %
0.477
1Y Rev Growth %
9.706
5Y Rev Growth %
10.322
NP Margin %
19.969
NP Margin 5Y Avg %
14.978
Trading Reference
1M Return %
2.688
6M Return %
-2.927
1Y Return %
-12.818
% Away 52W High
16.226
% Away 52W Low
6.919
Daily Volume
2088737
Investment Verdict
Risky
Score 57/100 · Position size: 6%
Higher volatility/weak areas. Consider only a small allocation if risk appetite is high.
Trading Verdict
Avoid
Score 24/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Sun Pharmaceutical Industries Ltd is currently trading near a key support level, with recent volume indicating strong buying interest. If it breaks above the resistance level established at the recent highs, there is potential for upward momentum. However, if it falls below the support, it could face significant downside risk.
Upside Probability: 15% | Downside Probability: 10%
Probability estimates are technical-context statements, not investment advice.
More Options
U
UltraTech Cement Ltd
UltraTech Cement Ltd shows decent fundamentals with growth potential, but investors should be cautious of cyclical risks and execution challenges.
View details
A
Axis Bank Ltd
Axis Bank shows potential for growth but faces challenges in profitability and execution risks.
View details
B
Bajaj Finserv Ltd
Bajaj Finserv Ltd shows decent potential with strong growth prospects and a solid business model, but valuation concerns and execution risks should be monitored.
View details
N
NTPC Ltd
NTPC Ltd shows potential for growth in a vital sector, but faces challenges related to profitability and valuation. Caution is advised for investors.
View details
H
Hindustan Aeronautics Ltd
Hindustan Aeronautics Ltd is well-positioned in a growing sector with strong fundamentals and a solid growth outlook.
View details
T
Titan Company Ltd
Titan Company Ltd shows a decent investment opportunity with strong fundamentals and growth potential, though some risks remain.
View details
A
Adani Ports and Special Economic Zone Ltd
Adani Ports presents a mixed outlook with significant risks, particularly in governance and market sentiment.
View details
A
Avenue Supermarts Ltd
Avenue Supermarts Ltd shows decent fundamentals with growth potential, but faces challenges in profitability and valuation compared to peers.
View details
O
Oil and Natural Gas Corporation Ltd
ONGC has a stable position in the energy sector but faces challenges that could impact future growth and profitability.
View details
B
Bharat Electronics Ltd
Bharat Electronics Ltd shows potential for growth in a future-ready sector, but valuation concerns and execution risks should be monitored.
View details
E
Eternal Ltd
Eternal Ltd shows potential but faces significant challenges in growth and profitability metrics. Caution is advised for investors.
View details
A
Adani Enterprises Ltd
Adani Enterprises Ltd shows potential in certain sectors but faces significant risks and challenges that could impact future performance.
View details
J
JSW Steel Ltd
JSW Steel Ltd shows decent potential with consistent growth and profitability metrics, but faces valuation concerns and execution risks.
View details
P
Power Grid Corporation of India Ltd
Power Grid Corporation of India Ltd shows decent fundamentals with growth potential, but faces valuation challenges and regulatory risks.
View details
W
Wipro Ltd
Wipro Ltd shows potential for growth but faces significant challenges in execution and market competition. Caution is advised.
View details
T
Tata Motors Ltd
Tata Motors has potential in the evolving automotive sector, particularly with electric vehicles, but faces challenges in growth consistency and profitability metrics.
View details
Business Overview
Sun Pharmaceutical Industries Ltd is a leading global specialty pharmaceutical company based in India, dedicated to improving patient health through innovative medicines. Catering to a diverse range of therapeutic areas, Sun Pharma serves healthcare professionals and patients across the globe. Its commitment to research and development, along with a robust product portfolio, positions it as a trusted partner in the pharmaceutical industry.
- Leading global specialty pharmaceutical company
- Focus on innovative and affordable medicines
- Strong presence in various therapeutic areas
- Robust research and development capabilities
- Commitment to quality and patient health
Investment Thesis
Sun Pharmaceutical Industries Ltd stands out as a compelling investment due to its robust promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. These factors position the company for sustained growth and profitability.
- Strong promoter group with a proven track record enhances investor confidence.
- Expansion into digital services opens new revenue streams and market opportunities.
- Currently trading at attractive valuations compared to industry peers, offering potential upside.
- Consistent focus on R&D ensures a robust pipeline of innovative products.
- Established global presence mitigates risks associated with domestic market fluctuations.
Opportunity vs Risk
Opportunities
- Strong product pipeline
- Expanding global footprint
- Rising demand for generics
- Strategic acquisitions
- Robust R&D capabilities
Risks ⚠️
- Regulatory challenges
- Intense market competition
- Currency fluctuations
- Patent expirations
- Supply chain disruptions
Peer Perspective
Sun Pharmaceutical Industries Ltd trades at a slight premium to peers like Dr. Reddy's and Cipla, reflecting its robust growth potential. A sustained improvement in margins could trigger a positive rerating in the stock.
Future Outlook
Sun Pharmaceutical Industries Ltd is poised for growth, driven by innovative product launches and expanding global markets. Successful execution of its strategic initiatives and effective cost control will be key to maximizing shareholder value.
AI FAQs for Retail Users
- Q: What does Sun Pharmaceutical Industries Ltd do?A: Sun Pharmaceutical is a leading global pharmaceutical company, focusing on manufacturing and marketing generic and specialty medicines.
- Q: Is Sun Pharmaceutical a good investment?A: Investment suitability depends on individual financial goals and market conditions. Conduct thorough research before investing.
- Q: What are the main products of Sun Pharmaceutical?A: Sun Pharmaceutical produces a wide range of medications, including generics, specialty drugs, and over-the-counter products.
- Q: How has Sun Pharmaceutical performed recently?A: Recent performance can be reviewed through financial reports and market analysis. Past performance does not guarantee future results.
- Q: Where can I find more information about Sun Pharmaceutical?A: You can visit their official website or check financial news platforms for updates and reports.
📊 Stock Investment Checklist (100 Points)
Sun Pharmaceutical Industries Ltd • Updated: 2025-09-18 09:48:46
-
10BusinessHighPharmaceutical sector is future-ready with strong demand.
-
10GrowthHighConsistent revenue growth over the past few years.
-
10ProfitabilityHighStrong ROE and OCF, but net profit margins are moderate.
-
8ValuationHighP/E ratio is slightly above industry average.
-
7BalanceHighDebt levels are manageable with good liquidity.
-
6GovernanceGoodPromoter holding is strong, but some pledging exists.
-
5DriversGoodGrowth drivers include new product launches, but execution risks remain.
-
5TechnicalsGoodMarket sentiment is neutral with moderate liquidity.
Final Score & Verdict
Score 68 / 100
• Decent
Sun Pharma shows decent fundamentals with growth potential but faces some execution risks.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 80/100
- Profitability: 70/100
- Governance: 65/100
- Market Confidence: 75/100